• PD 173074: FGFR1 Assay Workflows

  2026-10-01

  PD 173074 enables dose-tiered dissection of FGFR1 and VEGFR2 signaling in kinase, cell, and angiogenesis models. This guide converts its ATP-competitive mechanism into practical workflows, controls, and troubleshooting strategies for cancer research and vascular biology.

• Biotin-Tyramide: From Signal Gain to Spatial Insight

  2026-10-01

  A mechanistic and translational guide to Biotin-tyramide, explaining how HRP-driven biotin deposition converts molecular recognition into high-resolution signal amplification for IHC, ISH, and emerging biosensing workflows.

• Pazopanib Hydrochloride: From Kinase Maps to Response

  2026-09-30

  A translational framework for using Pazopanib Hydrochloride and GW786034 to connect multi-target kinase biology with more rigorous cancer-response measurements, especially in renal cell carcinoma and soft tissue sarcoma research.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-30

  This 2024 Journal of Ethnopharmacology study integrates network pharmacology with cellular and mouse experiments to investigate how Shenqi Fuzheng injection affects glioma growth and migration. Its central contribution is a cautiously supported link between SFI activity and SRC/PI3K/AKT signaling, accompanied by evidence of cell-cycle arrest, reduced migration-associated phenotypes, and slower tumor development.

• Sunitinib: Phosphoproteomic Assay Strategy

  2026-09-29

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with applications spanning angiogenesis, apoptosis, and cell-cycle research. This article uses a landmark Zika phosphoproteome study to develop a phosphosite-aware strategy for designing and interpreting Sunitinib experiments.

• Thioguanine Workflows for Cancer and EV71 Studies

  2026-09-29

  Thioguanine supports a unified workflow for cancer cell proliferation inhibition, epigenetic profiling, and EV71 virus inhibition, while its formulation requires careful DMSO handling. This practical guide connects benchmark activity with MIR9-centered acute lymphoblastic leukemia research and provides assay-ready optimization and troubleshooting advice.

• MG-262: Reversible Proteasome Inhibitor Guide

  2026-09-28

  MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a cell-permeable, reversible inhibitor of proteasome chymotryptic activity. It supports proteasome inhibition assay design, apoptosis research, and mechanistic studies of ubiquitin-dependent proteostasis, but it does not by itself establish a treatment for age-related muscle disease.

• ATRX Loss and RTK Inhibitor Sensitivity in Glioma

  2026-09-28

  Pladevall-Morera and colleagues report that ATRX-deficient high-grade glioma cells are more sensitive to several receptor tyrosine kinase and PDGFR inhibitors, with additional toxicity when RTK inhibition is combined with temozolomide. The findings support considering ATRX status in preclinical studies and clinical-trial analyses, while leaving the responsible receptor dependencies and clinical benefit to be established.

• Neuromedin S (rat): Handling and Assay Guide

  2026-09-27

  Neuromedin S (rat) provides a defined peptide ligand for controlled investigation of neuromedin U receptor signaling and GPCR/G protein responses. This guide covers preparation and assay controls; the reagent is for scientific research only and does not establish potency, therapeutic value, or performance in clinical or cross-species applications.

• Promethazine HCl for Macrophage Assays

  2026-09-26

  Use Promethazine HCl to probe histamine H1 signaling while testing whether phenothiazine treatment shifts macrophage ROS, lysosomal activity, autophagy, and intracellular bacterial control. A staged dose–response workflow helps separate these candidate effects from solvent toxicity and receptor-linked activity.

• 4-MUG Assays for Gaucher Disease Research

  2026-09-25

  4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) turns glycosidase activity into a quantifiable fluorescent signal, making it useful for lysosomal enzyme studies and GBA1-mRNA experiments. This guide connects assay setup to practical controls, optimization, and interpretation—without mistaking substrate turnover for a complete measure of disease correction.

• Pol II Degradation and Cell Death Beyond Transcription Loss

  2026-09-25

  A bioRxiv preprint reports that degrading RNA polymerase II (Pol II) can activate cell death in a way that is not explained simply by reduced transcription. The result highlights the need to distinguish loss of a protein from inhibition of its core activity, and to measure cell death directly when studying transcriptional perturbations.

• Acetylcholine Chloride for Gut–Brain Assays

  2026-09-24

  Use Acetylcholine Chloride as a controllable probe of cholinergic responses in gut–vagus–brain experiments—not as a stand-in for microbial treatment or endogenous neurotransmitter release. This workflow pairs practical concentration screening with circuit-level controls to help distinguish receptor responsiveness from whole-pathway effects.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib

  2026-09-24

  This study links elevated TRIB3 with adverse outcomes in clear cell renal cell carcinoma (ccRCC) and reports that TRIB3 knockdown promotes ferroptosis while increasing cellular sensitivity to sunitinib. The findings point to the SLC7A11/GPX4 antioxidant pathway as a mechanistic connection, while leaving important questions about in vivo efficacy and clinical translation unresolved.

• Pazopanib Hydrochloride: Beyond a Viability Readout

  2026-09-23

  Pazopanib Hydrochloride (GW786034) is a multi-target kinase inhibitor whose in vitro effects cannot be fully described by a single viability value. This article connects its pharmacology to a practical framework for separating growth arrest from cell killing and choosing assays that answer distinct research questions.

8384 records 1/559 page Next 12345 下5页 Last page